Targeting Inflammation with a New Drug for Arthritis
Author Information
Author(s): Lu Yingjuan, Stinnette Torian W, Westrick Elaine, Klein Patrick J, Gehrke Mark A, Cross Vicky A, Vlahov Iontcho R, Low Philip S, Leamon Christopher P
Primary Institution: Endocyte, Inc.
Hypothesis
Can a folate receptor-targeted drug improve treatment outcomes for arthritis with reduced toxicity?
Conclusion
The study found that EC0746 is a more effective and less toxic treatment for arthritis compared to traditional drugs like methotrexate.
Supporting Evidence
- EC0746 was found to be ~40-fold less toxic than unmodified aminopterin.
- EC0746 treatment resulted in ~91% inhibition in paw edema in rats.
- EC0746 showed a dose-dependent inhibition of cell proliferation in vitro.
Takeaway
Scientists created a new medicine that helps treat arthritis by targeting the bad cells causing inflammation, making it safer than older medicines.
Methodology
The study used rat models of arthritis to test the effects of EC0746 on inflammation and compared it to methotrexate and etanercept.
Potential Biases
Potential bias due to funding from the drug's manufacturer.
Limitations
The study was conducted in rats, which may not fully replicate human responses.
Participant Demographics
Female Lewis rats were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website